About US
Contact us
-
Expect a bump to GSK's Human Genome offer, but not a big oneInvestors and analysts alike expect GlaxoSmithKline ($GSK) to increase its bid for Human Genome Sciences ($HGSI), but not by much, Bloomberg reports. GSK probably will raise its $2.6 billion, $13-per-2012/6/13
-
FDA approves Roche's pricey new Herceptin partner, PerjetaRoche ($RHHBY) has added another targeted breast cancer drug to its oncology quiver. The FDA approved its new treatment for HER2-positive disease, pertuzumab, now dubbed Perjeta. It's a potential bloc2012/6/12
-
China now carries a big compulsory-licensing stickDrugmakers can count compulsory licensing among the new pitfalls of China's huge-and-growing drug market. Thanks to amended intellectual property laws, the Chinese government can now force generic dru2012/6/12
-
GSK extends $2.6 billion bid for Human Genome SciencesGlaxoSmithKline ($GSK) said it would and now it has. It extended its $2.6 billion hostile bid for shares of its partner Human Genome Sciences ($HGSI) by three weeks. The original offer fromGSKof $132012/6/11
-
UPDATED: FDA to look again at reclassifying hydrocodone combosCombination pain drugs like Vicodin from Abbott Laboratories ($ABT) are a pain for the Drug Enforcement Administration because they are easy to get and often abused. The DEA has again asked the FDA t2012/6/11
-
Pfizer readies documents for animal health IPOPfizer ($PFE) is prepping registration documents for an animal-health IPO. The company would offer a minority stake in the unit, dubbed Zoetis, as a step toward spinning off the unit completely. It's2012/6/8
-
Pharma feeds multiply on TwitterPharma may not be the most Twitter-savvy industry. But drugmakers have more toes in the Twitterverse than ever: According to Eye on FDA, at least 44 pharma companies have a Twitter feed, and altogethe2012/6/8
-
Study finds Roche's Actemra bests Abbott's blockbuster HumiraSwiss drug giant Roche ($RHHBY) today released data from a Phase IV study at the European League Against Rheumatism's annual conference in Berlin that showed its treatment Actemra--marketed in Euro2012/6/7
-
House would cut $16 million from FDA fundingA House appropriations proposal provides less FDA funding than the Senate or White House suggested and shaves $16.3 million off the current year's total, a comparison by an FDA support group shows.2012/6/7
-
Some drug recalls slip through FDA-reporting cracksThe FDA needs a new recall-alert system, researchers say. That's because some drug recalls--even the most serious, Class I type--haven't been adequately aired. "[W]e anticipate that a lot of provid2012/6/6